On December 9, 2021 ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported that the company will host a conference call and webcast to discuss their CD73 inhibitor program in multiple myeloma (Press release, ORIC Pharmaceuticals, DEC 9, 2021, View Source [SID1234596666]). On the call, management will be joined by Kenneth C. Anderson, M.D., Kraft Family Professor of Medicine at Harvard Medical School and Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, who will share his perspectives on CD73 inhibition and its promise in overcoming immune suppression in multiple myeloma.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Specifically, the call will focus on new ex vivo data from patients with multiple myeloma being presented at the American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, on the role of adenosine in immunosuppression, and on the ability of an ORIC CD73 inhibitor to restore antitumor immune activity as a single agent.
Details of the ASH (Free ASH Whitepaper) poster presentation are as follows:
Title: CD73 inhibition overcomes immunosuppression and triggers autologous T-cell mediated multiple myeloma cell lysis in the bone marrow milieu
Abstract #: 2675
Date & Time: Sunday, December 12, 2021, 6:00 – 8:00 pm ET
Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational
KOL Webcast and Conference Call Details
ORIC will host a conference call and webcast, Monday, December 13, 2021, at 5:30 p.m. ET. To participate in the conference call, please dial (833) 651-0991 (domestic) or (918) 922-6080 (international) and refer to conference ID 7989199. A live webcast and audio archive of the conference call will be available through the investor section of the company’s website at www.oricpharma.com. The webcast will be available for replay for 90 days following the presentation.